 Product DevelopmentThe company has 3 programs in place. The lead program, CVac™ has completed Phase IIa clinical trials and focuses on the development of an ex vivo immunotherapy for ovarian cancer.
>> |
|
 Scientific ResearchPrima BioMed's technologies all result from research on the human immune system. In summary, the technology platforms behind the Product Pipeline are: Dendritic cell therapy, Monoclonal Antibodies, DCtagTM adjuvant. >> |
|
 Clinical TrialCVac™ cell therapy is a new and groundbreaking technology for the treatment of cancer. It stimulates the production of immune cells, produced naturally in the body, that attack cancer cells. >> |
|
Latest News
28 July 2010
Latest Update on CVac >>
23 July 2010
First Patient Phase IIb Trial >>
03 June 2010
European Orphan Drug Designation >>
Read more news >> |